Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 15.8% in November

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a significant growth in short interest in November. As of November 30th, there was short interest totalling 11,000 shares, a growth of 15.8% from the November 15th total of 9,500 shares. Based on an average daily volume of 25,400 shares, the short-interest ratio is currently 0.4 days. Approximately 0.2% of the shares of the company are sold short.

Insider Buying and Selling

In related news, Director Bernd R. Seizinger bought 10,000 shares of the stock in a transaction on Friday, October 11th. The shares were bought at an average cost of $2.68 per share, for a total transaction of $26,800.00. Following the completion of the transaction, the director now owns 44,730 shares of the company’s stock, valued at $119,876.40. This represents a 28.79 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Marc Duey sold 6,462 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $4.58, for a total value of $29,595.96. Following the completion of the sale, the director now owns 233,651 shares in the company, valued at approximately $1,070,121.58. This represents a 2.69 % decrease in their position. The disclosure for this sale can be found here. Insiders bought 42,290 shares of company stock valued at $165,096 over the last ninety days. Corporate insiders own 12.80% of the company’s stock.

Institutional Trading of Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP purchased a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics at the end of the most recent reporting period. 34.19% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a report on Monday, November 18th.

Aprea Therapeutics Price Performance

APRE stock opened at $3.19 on Monday. The company’s 50 day simple moving average is $3.41 and its 200-day simple moving average is $3.59. Aprea Therapeutics has a 12 month low of $2.15 and a 12 month high of $8.85. The firm has a market capitalization of $17.34 million, a PE ratio of -1.14 and a beta of 0.88.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.11. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. The firm had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.45 million. As a group, sell-side analysts anticipate that Aprea Therapeutics will post -2.55 earnings per share for the current year.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.